Arcturus Therapeutics Holdings Inc. (ARCT) vs Eikon Therapeutics, Inc. Common Stock (EIKN)

A side-by-side comparison of Arcturus Therapeutics Holdings Inc. and Eikon Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Arcturus Therapeutics Holdings Inc. logo
ARCT
Arcturus Therapeutics Holdings Inc.
$378M
$13.31HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT
Eikon Therapeutics, Inc. Common Stock logo
EIKN
Eikon Therapeutics, Inc. Common Stock
$416M
$7.68HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT

Total return — ARCT vs EIKN

growth of $100 · dividends reinvested · last 1y
ARCT +108.8% (+108.8%/yr)EIKN -49.7% (-49.7%/yr)ARCT compounded faster over this window
50100150200250Start $100$209$50
ARCT EIKN

ARCT vs EIKN: by the numbers

  • •EIKN is the larger company ($416M vs $378M market cap).
  • •Both run net losses; EIKN's is the smaller (0.00% vs -391.90% net margin).

Metrics side by side

Valuation

MetricARCTEIKN
P/S ratio15.89N/A
P/B ratio2.200.89

Profitability

MetricARCTEIKN
Gross margin95.50%0.00%
Operating margin-111.51%0.00%
Net margin-391.90%0.00%
ROE-54.29%-69.06%
ROIC-54.07%-46.16%

Growth (annualized)

MetricARCTEIKN
Revenue CAGR (5Y)22.30%N/A
Total return CAGR (5Y)-18.73%N/A

Go deeper

Full ARCT analysisFull EIKN analysisInteractive comparison tool

Dig into the metrics

Arcturus Therapeutics ROEEikon Therapeutics, Inc. Common Stock ROEArcturus Therapeutics operating marginEikon Therapeutics, Inc. Common Stock operating marginArcturus Therapeutics revenue growthEikon Therapeutics, Inc. Common Stock revenue growthArcturus Therapeutics free cash flowEikon Therapeutics, Inc. Common Stock free cash flow

Arcturus Therapeutics & Eikon Therapeutics, Inc. Common Stock appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.